Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $385.00 at Canaccord Genuity Group

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Canaccord Genuity Group from $384.00 to $385.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Scotiabank dropped their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $299.48.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $252.49 on Tuesday. The business has a fifty day moving average of $254.04 and a 200 day moving average of $263.12. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market capitalization of $32.69 billion, a price-to-earnings ratio of -116.36 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, research analysts expect that Alnylam Pharmaceuticals will post -1.94 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,356 shares of company stock worth $22,498,551. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of ALNY. GF Fund Management CO. LTD. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $637,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $203,000. Worldquant Millennium Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 156.6% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after purchasing an additional 91,671 shares during the last quarter. Zurich Insurance Group Ltd FI acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $6,583,000. Finally, Vident Advisory LLC grew its position in Alnylam Pharmaceuticals by 21.2% in the 4th quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 232 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.